why choose us

Clinical Trials Search

Showing 15,600 of 132,963 result(s)
Empagliflozin in Patients With Cirrhosis and Ascites

Status: Completed

Condition: Cirrhosis

Interventions: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days.
A 14 day washout period follows and then participants is crossed o

Date: 2023-02-02

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

Status: Completed

Condition: Breast Carcinoma

Interventions: APC activator, MHC II agonist

Date: 2023-02-02

Pancreatic Clamp in NAFLD

Status: Completed

Condition: Insulin Resistance

Interventions: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basa

Date: 2023-02-02

Brief Versus Standard Cognitive Behavioral Therapy for Insomnia in Veterans

Status: Completed

Condition: Insomnia

Interventions: 4 session CBT-I

Date: 2023-02-02

Chronic Postsurgical Pain

Status: NOT_YET_RECRUITING

Condition: Cerebral Palsy

Interventions:

Date: 2023-02-02

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

Status: Completed

Condition: Hiv Prevention

Interventions: Participants will receive either Truvada or Descovy (based on prescription guidelines).

Date: 2023-02-02

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Status: Completed

Condition: Recurrent Acute Leukemia of Ambiguous Lineage

Interventions: Undergo collection of blood and bone marrow samples

Date: 2023-02-02

Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy

Status: Completed

Condition: Hemorrhage

Interventions: Single arm, healthy adult volunteers for blood donation.

Date: 2023-02-02

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Status: Completed

Condition: Hepatobiliary Cancer

Interventions: Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any othe

Date: 2023-02-02